Today: 19 May 2026
Browse Category

NYSE:ABBV 23 December 2025 - 10 January 2026

AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie shares fell 1.8% to $220.08 Friday after the company cut its Q4 and 2025 profit forecasts, citing a $1.3 billion charge for acquired R&D and milestone expenses. The company denied rumors of takeover talks with Revolution Medicines. AbbVie will present at the J.P. Morgan Healthcare Conference on Jan. 14 and report earnings on Feb. 4.
10 January 2026
···
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie shares fell 1.8% to $220.08 after the company cut its 2025 earnings forecast and denied takeover talks with Revolution Medicines. AbbVie now expects Q4 adjusted EPS of $2.61–$2.65, down from $3.32–$3.36, and full-year EPS of $9.90–$9.94. The company cited $1.265 billion in R&D and milestone charges. AbbVie said its fourth-quarter results are preliminary.
10 January 2026
···
AbbVie stock slips on $1.3B charge, deal-rumor denial — what’s next for ABBV

AbbVie stock slips on $1.3B charge, deal-rumor denial — what’s next for ABBV

AbbVie shares fell 0.8% to $222.35 after the company cut its 2025 profit outlook and denied takeover talks with Revolution Medicines. AbbVie now expects fourth-quarter adjusted EPS of $2.61–$2.65, down from $3.32–$3.36, citing a $1.3 billion pre-tax acquired R&D expense. Wolfe Research downgraded the stock to “Peer Perform.” AbbVie said results for the quarter ended Dec. 31 are not yet final.
9 January 2026
··
AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

AbbVie shares fell 4% to $224.13 in after-hours trading Thursday after the company cut its 2025 adjusted profit forecast and disclosed a $1.3 billion acquired R&D charge. The company lowered its full-year 2025 adjusted EPS outlook to $9.90–$9.94 from $10.61–$10.65. AbbVie denied takeover talks with Revolution Medicines. Investors await the company’s Feb. 4 earnings report for further guidance.
9 January 2026
···
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie shares fell 3.7% to $224.84 Thursday after the company denied takeover talks with Revolution Medicines and flagged a $1.3 billion fourth-quarter charge tied to R&D and milestone payments. AbbVie trimmed its 2025 profit forecast, setting adjusted earnings at $9.90 to $9.94 per share. Revolution Medicines dropped 5.5%. Wolfe Research downgraded AbbVie, citing limited upside.
8 January 2026
··
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie shares fell 1.6% to $229.64 premarket after the company denied talks to acquire Revolution Medicines and cut its 2025 profit forecast. Revolution stock dropped 11.5% following AbbVie’s statement. AbbVie now expects 2025 adjusted EPS of $9.90 to $9.94, down from its previous outlook, citing a $1.3 billion acquired IPR&D charge. Earnings are due Feb. 4.
8 January 2026
···
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie shares fell 1% to $231.11 in after-hours trading after the company denied reports of takeover talks with Revolution Medicines. A new SEC filing flagged a $1.3 billion fourth-quarter charge, prompting AbbVie to cut its 2025 adjusted earnings forecast to $9.90–$9.94 per share from $10.61–$10.65. Revolution shares dropped 11.5% late.
8 January 2026
····
AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

Health Canada approved AbbVie’s Maviret for acute and chronic hepatitis C in adults and children aged 3 and older. AbbVie shares were flat premarket at $220.18 after falling nearly 4% Monday. The approval followed a Priority Review based on Phase 3 data. Investors await AbbVie’s Jan. 14 appearance at the J.P. Morgan Healthcare Conference.
6 January 2026
··
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie shares closed down 4% at $220.18 on Monday, underperforming a market rally that sent the Dow to a record. Trading volume reached 8.9 million shares, well above the 50-day average. The stock now sits below key technical levels ahead of its Jan. 14 presentation at the J.P. Morgan Healthcare Conference and expected late-January earnings.
6 January 2026
·····
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie shares rose 0.2% to $228.95 after Ironwood Pharmaceuticals, its Linzess partner, raised 2026 U.S. net sales guidance and cut the drug’s list price effective Jan. 1. Ironwood shares jumped 29.5%. Ironwood now expects 2026 Linzess U.S. net sales of $1.125–$1.175 billion, up from 2025’s $860–$890 million forecast. Wall Street trading was muted as investors awaited U.S. labor data and watched for broader drug pricing moves.
2 January 2026
···
AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie closed Friday at $229.98, near its 52-week high, as U.S. markets ended a quiet post-holiday session with major indexes little changed. No major AbbVie corporate news broke in the past two days, but investor analysis and institutional filings kept the stock in focus. Institutions and hedge funds hold about 70% of shares. The next regular trading session is Monday.
27 December 2025
···
AbbVie Stock (ABBV) Before the Market Opens Dec. 26, 2025: Today’s News, Earnings Outlook, Dividend Update, and Analyst Forecasts

AbbVie Stock (ABBV) Before the Market Opens Dec. 26, 2025: Today’s News, Earnings Outlook, Dividend Update, and Analyst Forecasts

AbbVie shares closed at $229.89 in a shortened Dec. 24 session, near their 52-week high of $244.81. The company reported Q3 2025 net revenues of $15.776 billion, with Skyrizi and Rinvoq sales outpacing declining Humira revenue. Markets reopen Dec. 26 after the Christmas holiday. AbbVie recently announced a dividend increase effective February 2026.
26 December 2025
·
AbbVie (ABBV) Stock After Hours Today (Dec. 23, 2025): Key News, Forecasts, and What to Watch Before the Market Opens Dec. 24

AbbVie (ABBV) Stock After Hours Today (Dec. 23, 2025): Key News, Forecasts, and What to Watch Before the Market Opens Dec. 24

AbbVie shares closed at $228.79 Tuesday, up 0.4%, and traded near $229.60 after hours. Trading volume was thin ahead of Wednesday’s early market close for Christmas Eve. Investors tracked U.S. drug pricing talks, AbbVie’s pipeline beyond Botox, and a late legal update on Orilissa. AbbVie remains in its 52-week range of $164 to $245.
24 December 2025
··
AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie shares traded near $228.62 Tuesday afternoon, up 0.31%, as investors weighed new pipeline updates and continued debate over U.S. drug pricing. PharmaVoice reported AbbVie is advancing two next-generation neurotoxins, AGN-151607 and TrenibotE, for both aesthetic and therapeutic uses. Nasdaq highlighted strong Skyrizi and Rinvoq sales, projecting over $25 billion combined in 2025.
23 December 2025
·
1 2 3 4 5

Stock Market Today

  • Chart Patterns Signal Potential Rise in Treasury Yields Amid New Interest Rate Era
    May 19, 2026, 7:15 AM EDT. A "pennant" chart pattern suggests U.S. Treasury yields could climb significantly, indicating a possible shift to a higher interest rate environment. Treasury yields, which reflect government borrowing costs and influence borrowing rates economy-wide, have remained volatile amid economic uncertainty. The pattern warns investors to brace for rising rates, which could pressure bonds and stocks. However, analysts note an alternative scenario where yields might not surge as much, adding complexity to market outlooks. This development underscores the challenges in forecasting fixed income markets and the potential for renewed volatility.

Latest articles

Meiwu Technology Stock Jumps 88% Premarket After Monday Rout — What’s Moving WNW Now

Meiwu Technology Stock Jumps 88% Premarket After Monday Rout — What’s Moving WNW Now

19 May 2026
Meiwu Technology shares surged 87.99% to $4.531 in premarket trading Tuesday after a 22.76% drop Monday, which left the stock at $2.410. The company recently raised $15.65 million in a private share sale at $0.626 per share, with proceeds earmarked for an AI-driven skincare platform and related projects. Meiwu reported 2025 revenue of $7.08 million and a net loss of $18.59 million.
Standard Chartered’s Push Into AI May Cut 7,000 Jobs as Bank Looks for 18% Returns

Standard Chartered’s Push Into AI May Cut 7,000 Jobs as Bank Looks for 18% Returns

19 May 2026
Standard Chartered will cut over 7,000 jobs by 2030 and aims for an 18% return on tangible equity, focusing on AI and automation to boost efficiency. The bank reported record Q1 operating income of $5.9 billion and profit before tax of $2.5 billion. Job cuts will mainly affect corporate and support roles in hubs like Bengaluru, Tianjin, and Warsaw. The bank seeks to attract $200 billion in new wealth by 2028.

Popular

Destiny Tech100 Gains Pre-Market as SpaceX IPO Buzz Mixes With AI Stock Warnings

Destiny Tech100 Gains Pre-Market as SpaceX IPO Buzz Mixes With AI Stock Warnings

18 May 2026
Destiny Tech100 Inc. shares rose 10.6% to $52.68 in early premarket trading Monday after reports that SpaceX may list on Nasdaq as soon as June 12 at a $1.75 trillion valuation. DXYZ’s portfolio includes about 14.4% exposure to SpaceX and 18.1% to Anthropic. The stock ended last week down 13% despite sharp swings. Destiny’s shares last closed at nearly double their reported net asset value.
Go toTop